Preparation, pharmacokinetics and pharmacodynamics of ophthalmic thermosensitive in situ hydrogel of betaxolol hydrochloride

Biomedicine and Pharmacotherapy

Volumn 83, Issue , 2016, Pages 107-113

  Huang, Weiwei ^a   Zhang, Nan ^a   Hua, Haiying ^a   Liu, Tuanbing ^a   Tang, Yafang ^a   Fu, Lingling ^a   Yang, Yanan ^a   Ma, Xiujie ^a   Zhao, Yongxing ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Betaxolol hydrochloride; In situ hydrogel; Ophthalmic delivery system; Poloxamer; Polycarbophil

Indexed keywords

BETAXOLOL; GELLING AGENT; POLOXAMER; POLYCARBOPHIL; EYE DROPS; HYDROGEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG STABILITY; DRUG SYNTHESIS; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; LOW TEMPERATURE; MAXIMUM PLASMA CONCENTRATION; MUCOADHESION; NONHUMAN; PH; PHARMACODYNAMICS; PRIORITY JOURNAL; RABBIT; RESPONSE SURFACE METHOD; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISCOSITY; ANIMAL; DRUG EFFECTS; DRUG RELEASE; EYE; FLOW KINETICS; KINETICS; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACOKINETICS; PHARMACOLOGY; RABBITS AND HARES; SYNTHESIS; TEMPERATURE;

ANIMALS; BETAXOLOL; DRUG LIBERATION; EYE; HYDROGEL; INTRAOCULAR PRESSURE; KINETICS; OPHTHALMIC SOLUTIONS; RABBITS; RHEOLOGY; TEMPERATURE;

EID: 84975841196     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.06.024     Document Type: Article

References (31)

1. [1] Gaudana, R., Jwala, J., Boddu, S.H.S., Mitra, A.K., Recent perspectives in ocular drug delivery. Pharm. Res.-Dord. 26:5 (2009), 1197–1216.
2. [2] Chen, H., Recent developments in ocular drug delivery. J. Drug Target. 23:7–8 (2015), 597–604.
3. [3] Li, J., Wu, L., Wu, W., Wang, B., Wang, Z., Xin, H., Xu, Q., A potential carrier based on liquid crystal nanoparticles for ophthalmic delivery of pilocarpine nitrate. Int. J. Pharm. 455:1–2 (2013), 75–84.
4. [4] Badhani, A., Dabral, P., Rana, V., Upadhyaya, K., Evaluation of cyclodextrins for enhancing corneal penetration of natamycin eye drops. J. Pharm. Bioallied Sci. 4:Suppl. 1 (2012), S29–30.
5. [5] Ranjbar, A.A.S., Rajabi, O., Salari, R., Ashraf, H., Lidocaine cyclodextrin complex ophthalmic drop, a new topical anesthetic choice. Iran. Red Crescent Med. 14:9 (2012), 569–573.
6. [6] Bhowmik, M., Kumari, P., Sarkar, G., Bain, M.K., Bhowmick, B., Mollick, M.M., Mondal, D., Maity, D., Rana, D., Bhattacharjee, D., Chattopadhyay, D., Effect of xanthan gum and guar gum on in situ gelling ophthalmic drug delivery system based on poloxamer-407. Int. J. Biol. Macromol. 62 (2013), 117–123.
7. [7] Gevariya, H.B., Patel, J.K., Long acting betaxolol ocular inserts based on polymer composite. Curr. Drug Deliv. 10:4 (2013), 384–393.
8. [8] Agrawal, A.K., Das, M., Jain, S., In situ gel systems as ‘smart’ carriers for sustained ocular drug delivery. Expert Opin Drug Del 9:4 (2012), 383–402.
9. [9] Mundada, A.S., Avari, J.G., In situ gelling polymers in ocular drug delivery systems: a review. Crit. Rev. Ther. Drug 6:1 (2009), 85–118.
10. [10] Yin, H., Gong, C., Shi, S., Liu, X., Wei, Y., Qian, Z., Toxicity evaluation of biodegradable and thermosensitive PEG-PCL-PEG hydrogel as a potential in situ sustained ophthalmic drug delivery system. J. Biomed. Mater. Res. Part B Appl. Biomater. 92:1 (2010), 129–137.
11. [11] Li, J., Liu, H., Liu, L.L., Cai, C.N., Xin, H.X., Liu, W., Design and evaluation of a brinzolamide drug-resin in situ thermosensitive gelling system for sustained ophthalmic drug delivery. Chem. Pharm. Bull. 62:10 (2014), 1000–1008.
12. [12] Tirnaksiz, F., Robinson, J.R., Rheological, mucoadhesive and release properties of Pluronic F-127 gel and Pluronic F-127/polycarbophil mixed gel systems. Pharmazie 60:7 (2005), 518–523.
13. [13] Cao, F., Zhang, X.L., Ping, Q.N., New method for ophthalmic delivery of azithromycin by poloxamer/carbopol-based in situ gelling system. Drug Deliv. 17:7 (2010), 500–507.
14. [14] Wang, L.L., Zheng, W.S., Chen, S.H., Fang, X.Q., Development of In situ gelling and bio adhesive 5-fluorouracil enema. PLoS One, 8(8), 2013.
15. [15] Shankar, G.N., Alt, C., Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection. J. Antimicrob. Chemother. 69:12 (2014), 3282–3293.
16. [16] Plager, D.A., Whitson, J.T., Netland, P.A., Vijaya, L., Sathyan, P., Sood, D., Krishnadas, S.R., Robin, A.L., Gross, R.D., Scheib, S.A., Scott, H., Dickerson, J.E., Grp, B.S.P.S., Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial. J. AAPOS 13:4 (2009), 384–390.
17. [17] Qi, H.Y., Chen, W.W., Huang, C.Y., Li, L., Chen, C.M., Li, W.M., Wu, C.J., Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int. J. Pharm. 337:1–2 (2007), 178–187.
18. [18] Zhang, J., Li, Y., Fang, X., Zhou, D., Wang, Y., Chen, M., TPGS-g-PLGA/Pluronic F68 mixed micelles for tanshinone IIA delivery in cancer therapy. Int. J. Pharm. 476:1–2 (2014), 185–198.
19. [19] Mandal, S., Thimmasetty, M.K., Prabhushankar, G., Geetha, M., Formulation and evaluation of an in situ gel-forming ophthalmic formulation of moxifloxacin hydrochloride. Inte. J. Pharm. Investig. 2:2 (2012), 78–82.
20. [20] Lin, H.R., Sung, K.C., Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J. Control. Release 69:3 (2000), 379–388.
21. [21] Abrego, G., Alvarado, H., Souto, E.B., Guevara, B., Bellowa, L.H., Parra, A., Calpena, A., Garcia, M.L., Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration. Eur. J. Pharm. Biopharm. 95 (2015), 261–270.
22. [22] Peppas, N.A., Sahlin, J.J., A simple equation for the description of solute release. III. coupling of diffusion and relaxation. Int. J. Pharm. 57 (1989), 169–172.
23. [23] Xie, L., Beyer, S., Vogel, V., Wacker, M.G., Mantele, W., Assessing the drug release from nanoparticles: overcoming the shortcomings of dialysis by using novel optical techniques and a mathematical model. Int. J. Pharm. 488:1–2 (2015), 108–119.
24. [24] Desai, S.D., Blanchard, J., In vitro evaluation of pluronic F127-based controlled-release ocular delivery systems for pilocarpine. J. Pharm. Sci. 87:2 (1998), 226–230.
25. [25] Fatima, A., Iftekhar, G., Sangwan, V.S., Vemuganti, G.K., Ocular surface changes in limbal stem cell deficiency caused by chemical injury: a histologic study of excised pannus from recipients of cultured corneal epithelium. Eye 22:9 (2008), 1161–1167.
26. [26] Shi, S., Zhang, Z., Luo, Z., Yu, J., Liang, R., Li, X., Chen, H., Chitosan grafted methoxy poly(ethylene glycol)-poly(epsilon-caprolactone) nanosuspension for ocular delivery of hydrophobic diclofenac. Sci. Rep., 5, 2015, 11337.
27. [27] Jain, K., Kumar, R.S., Sood, S., Dhyanandhan, G., Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy. Curr. Drug Deliv. 10:5 (2013), 493–499.
28. [28] Ding, S., Chen, C.C., Salome-Kesslak, R., Tang-Liu, D.D., Himmelstein, K.J., Precorneal sampling techniques for ophthalmic gels. J. Ocul. Pharmacol. 8:2 (1992), 151–159.
29. [29] Reddy, I.K., Vaithiyalingam, S.R., Khan, M.A., Bodor, N.S., Intraocular pressure-lowering activity and in vivo disposition of dipivalyl terbutalone in rabbits. Drug Dev. Ind. Pharm. 27:2 (2001), 137–141.
30. [30] Zhu, M.D., Cai, F.Y., Development of experimental chronic intraocular hypertension in the rabbit. Aust. N. Z. J. Ophthalmol. 20:3 (1992), 225–234.
31. [31] Jamroz-Piegza, M., Utrata-Wesolek, A., Trzebicka, B., Dworak, A., Hydrophobic modification of high molar mass polyglycidol to thermosensitive polymers. Eur. Polym. J. 42:10 (2006), 2497–2506.